Takumi Imai

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Yohei Doi, Masaya Hibino, Ryota Hase et al. · Antimicrobial Agents and Chemotherapy · 2020 · 231 citations · Full text

Open-label Trial, Late Favipiravir Therapy, Clinical Infectious Disease +14

Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older (EWTOPIA 75)

Yasuyoshi Ouchi, Junichi Sasaki, Hidenori Arai et al. · Circulation · 2019 · 208 citations · Full text

Localization of metallothionein in nuclei of growing primary cultured adult rat hepatocytes

Kazutake Tsujikawa, Takumi Imai, Makoto Kakutani et al. · FEBS Letters · 1991 · 123 citations · Full text

Hepatology, Biochemistry, Liver Physiology +14

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 118 citations · Full text

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus et al. · Kidney International · 2021 · 92 citations · Full text